EQT Corporation receives a Strong Buy rating with a $93.59/share price target, driven by robust domestic gas power and LNG export demand. EQT's vertically integrated upstream and midstream assets, including a 53% stake in MVP Mainline, position it to capitalize on rising data center and LNG-driven gas demand. Operational improvements, cost efficiencies, and strategic infrastructure investments are expected to drive production yields and support free cash flow of ~$3.5b in eFY26.
EQT Corporation (EQT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Does EQT Corporation (EQT) have what it takes to be a top stock pick for momentum investors? Let's find out.
EQT (EQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
EQT (EQT) reported earnings 30 days ago. What's next for the stock?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
With mega-cap tech names dominating many equities conversations in recent quarters, investors might be seeking an alternative with a bit more breadth. So-called GARP stocks—named because of their potential to provide "growth at a reasonable price"—aim to combine elements of value and growth names in a single investment.
EQT shares rise 31% in a year as rising natural gas demand, stronger prices and robust free cash flow boost the outlook, though higher costs and price volatility pose risks.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Private equity group EQT said on Wednesday it had decided not to proceed with a takeover offer for Oxford Biomedica , sending the British cell and gene therapy manufacturer's shares down nearly 10%.